Skip to main content
. 2022 Oct 10;13:928945. doi: 10.3389/fimmu.2022.928945

Figure 1.

Figure 1

(A) Proportion of HHV-6-positive and -negative individuals in the control group and the ME/CFS patient group. (B) Proportion of individuals in the control group and the ME/CFS patient group with detected HHV-6A and HHV-6B. (C) Proportion of HHV-6-positive and -negative patients with different ME/CFS severity; “no”—without HHV-6 genomic sequence in blood DNA, “yes”—with HHV-6 genomic sequence in blood DNA. (D) Number of control individuals and of mild, moderate, and severe ME/CFS disease course patients with viral load < 1,000 copies/106 PBMCs and > 1,000 copies/106 PBMCs. (E) Proportion of control individuals and ME/CFS patients with viral load < 1,000 copies/106 PBMCs and > 1,000 copies/106 PBMCs. f, ,female; m, male.